NSE filing, NSE: ONESOURCE. Summary written from the filing by ALFA Finder's alert engine.
OneSource Specialty Pharma Ltd: key numbers
- Share price
- ₹1,577.60
- Market cap
- ₹18,091 Cr
- Revenue (annual)
- ₹1,422 Cr
- Net profit (annual)
- ₹-73.80 Cr
- P/E (TTM)
- -11160.2×Sector 46.1×
- Promoter holding
- 30.47%-0.01% QoQ
- FII holding
- 19.45%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from OneSource Specialty Pharma Ltd
All →OneSource Specialty Pharma Earnings Call Transcript: Key Takeaways
Onesource Specialty Pharma delivered its third consecutive growth quarter, driven by new sterile cartridge capacity.
OneSource Specialty Pharma Results Update
OneSource announced Q2FY27 results with revenue up 37% YoY and EBITDA up 53% YoY. An investor presentation was filed alongside the press release.
OneSource Specialty Pharma Employee Stock Options
OneSource Specialty Pharma allotted 360 equity shares under its ESOP 2021 scheme to an eligible employee. Paid-up share capital increased to 11,46,74,151 shares of ₹1 each.
OneSource Specialty Pharma Management Change
Dr. Claudio Albrecht's designation changed from Independent Director to Non-Executive Non-Independent Director, effective 27 Oct 2026. The change is subject to shareholder approval at the upcoming meeting.
OneSource Specialty Pharma Q2 FY27 Results: Net Profit ₹57.5 Cr, Up 447.6% YoY
OneSource Specialty Pharma Ltd reported revenue from operations of ₹516.2 Cr (+37.4% YoY) and net profit of ₹57.5 Cr (+447.6% YoY) for Q2 FY27.
- Key figure
- Net profit ₹57.5 Cr · +447.6% YoY
OneSource Specialty Pharma Board Meeting Date
OneSource Specialty Pharma Limited scheduled a board meeting for October 27, 2026, to consider the company's unaudited financial results for the quarter ended September 2026.
Other regulatory approval announcements
All →Shalby Regulatory Approval
Shalby Hospital, Jabalpur received CMHO permission to resume normal operations, including patient admissions, on its previously affected floor. The hospital has now fully resumed healthcare services.
Elantas Beck India Regulatory Approval
Elantas Beck India's GPCB permanently revoked the closure direction on its Ankleshwar plant. The facility can keep operating, subject to compliance conditions.
Kalyani Cast-Tech Regulatory Approval
Kalyani Cast-Tech received RDSO Stage-I concept design approval for its new container-carrying wagon under PWDA. Stage-II detailed design approval is still required, subject to dynamics simulation conditions.
Mukka Proteins Regulatory Approval
Mukka Proteins received a US FDA facility registration certificate, valid October 1, 2026 to December 31, 2027. The company says the registration supports its engagement with US customers and markets.
- Execution
- October 1, 2026 to December 31, 2027
Canara Bank Regulatory Approval
Canara Bank received RBI permission to exercise the call option on its Basel III AT1 bonds (ISIN INE476A08134) of Rs.1,500 Crore. The bank is now in process of exercising the call as per the issue terms.
- Value
- ₹1,500 Cr
Alembic Pharmaceuticals Regulatory Approval
Alembic Pharmaceuticals received USFDA final approval for Valganciclovir for Oral Solution, 50 mg/mL. This adds to its cumulative 247 USFDA ANDA approvals.